Covid: third dose of Pfizer 95.6% effective against the virus, the laboratory claims

Published by Cécile D. · Photos by Rizhlaine F. · Updated on 25 October 2021 at 09h38 · Published on 21 October 2021 at 17h29
Pfizer-BioNTech has carried out a study showing their booster shot is 95.6% effective against symptomatic Covid-19.

In France, the fight against Covid-19 goes on with a booster shot vaccine campaign. As of October 6, 2021, only 7% of people eligible have been given their third dose of the vaccine. The French government is regularly encouraging vulnerable people to get their booster shot to prevent a fifth wave.

The latest study conducted by drugmakers Pfizer and BioNTech may convince the stubborn ones. According to an assessment conducted by both laboratories and issued this Thursday October 21, the third dose of Pfizer injected in patients is 95.6% effective against symptomatic coronavirus.

These are the first efficacy results from any randomized, controlled COVID-19 vaccine booster trial”, the laboratories claim as they have planned to submit their study to the regulatory authorities as soon as possible.

This assessment has been conducted as a phase 3 clinical trial gathering 10,000 people aged 16+. Results are very encouraging since the study has been carried out when “Delta was the prevalent strain” during this period.

In a press release, Pfizer CEO Albert Bourla uses this study to show the importance of vaccination: “These results provide further evidence of the benefits of boosters as we aim to keep people well-protected against this disease”.

Practical information

Refine your search
Refine your search
Refine your search
Refine your search